Molecular mechanisms of transdifferentiation
转分化的分子机制
基本信息
- 批准号:7380265
- 负责人:
- 金额:$ 16.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-09-10 至 2009-08-31
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs DiseaseAntibodiesAntigensAutologousB-LymphocytesBone MarrowCause of DeathCell AgingCell LineCell LineageCell Surface ProteinsCell membraneCell surfaceCellsCharacteristicsCoculture TechniquesComplementComplement Factor BDNADNA Sequence RearrangementDataDetectionDiabetes MellitusDiseaseEnsureEnvironmentEnzyme GeneEnzymesErinaceidaeEventExhibitsExposure toFutureGenesGreen Fluorescent ProteinsHandHeart DiseasesIGH@ gene clusterImmunoglobulinsIndividualIntermediate FilamentsKeratinKineticsLabelLigandsLymphocyteMediatingMembraneMesenchymalMolecularMonitorMusMutationNumbersOrganPersonal SatisfactionPhenotypePolymerase Chain ReactionPopulationProcessProteinsProto-Oncogene Protein c-kitSkinStagingStem cellsStromal CellsTestingTimeTissuesV(D)J Recombinationadult stem cellcell agecell typeclinically significantcytokineembryonic stem cellepidermis cellkeratin 14, K14keratin 5keratinocytenotch proteinpaired box 5 protein (B-cell lineage specific activator)panaceaprotein Breceptorrecombinaseresponsetissue regenerationtranscription factortransdifferentiation
项目摘要
DESCRIPTION (provided by applicant): Transdifferentiation has become a common claim for somatic stem cells, yet how this is accomplished has not been well investigated. Although much evidence exists that somatic stem cells can change their protein phenotype, it is not clear what mechanisms are involved, and whether the stem cells actually change their function and maintain this change. To investigate the mechanisms of transdifferentiation, we propose to use two cell types with distinct characteristics and functions: the epidermal stem cell (EpiSC) and the B lymphocyte. EpiSCs express the intermediate filaments keratins 5 and 14 and form sheets of cells connected by adherens and desmosomal junctions. B lymphocytes, in contrast, do not express keratin intermediate filaments. They express a defined set of cell surface proteins with well-studied kinetics of expression. In order for a B lymphocyte to produce a specific immunoglobulin, it must incur a permanent genetic change. This involves deletion and rearrangement of VDJ segments in their immunoglobulin heavy chain locus. This rearrangement is mediated by the RAG1 and RAG2 recombinase enzymes, and by the Pax5-encoded transcription factor BSAP (B cell specific activator protein). EpiSCs do not exhibit VDJ rearrangement; express the RAG1, RAG2, or Pax5 gene; or produce immunoglobulin. Our preliminary data suggest that EpiSCs can be directed to express the B lymphocyte cell markers and genes, and show rearrangement of VDJ segments. We hypothesize that EpiSCs are developmentally flexible, i.e. that they can be directed to produce cells of alternate lineages. To test this hypothesis, in Aim 1, we propose to direct EpiSCs (marked with 2gal) to transdifferentiate into B lymphocytes. We will verify that individual EpiSCs did transdifferentiate by detection of B cell surface markers and recombinase enzyme genes, and by PCR analysis for VDJ rearrangement in 2gal-expressing cells. Since permanency of the transdifferentiation event is important for future therapy, we will test whether or not EpiSCs that alter their cell lineage remain transdifferentiated when removed from the B cell inductive environment. In Aim 2, we will attempt to determine the mechanism(s) by which individual EpiSCs transdifferentiate. Our preliminary findings indicate that EpiSCs require direct contact with the S17 stromal cells in order to transdifferentiate. We hypothesize that S17 cells induce EpiSCs to alter their lineage via receptor- ligand interaction(s). We will test this hypothesis by examining the membranes of EpiSCs, before and during co-culture with S17 cells, for the expression of candidate receptor-ligand pairs. Since the skin is the largest organ with potentially the greatest number of stem cells, understanding the mechanism behind transdifferentiation of these cells is a step toward their use in tissue regeneration. Many diseases, including diabetes, Alzheimer's, and heart disease, are caused by the death of cells in major organs. To treat these diseases, the lost cells must be replaced, ideally with autologous cells. Such cells will have to be induced to change their lineage and engraft into a new environment, a process collectively called transdifferentiation. Stem cells from the epidermis, the outer layer of the skin, offer advantages over other types of adult stem cells in that they can be isolated with little harm to the individual and, since the skin is the largest organ in the body, they are present in large quantities. Therefore, determining the mechanism behind transdifferentiating epidermal stem cells and their potential for tissue regeneration has clinical significance.
描述(由申请人提供):转分化已成为体干细胞的一种常见说法,但如何实现这一点尚未得到很好的研究。虽然有很多证据表明,体干细胞可以改变它们的蛋白质表型,但尚不清楚涉及的机制,以及干细胞是否真的改变了它们的功能并保持这种变化。为了研究转分化的机制,我们建议使用两种具有不同特征和功能的细胞类型:表皮干细胞(EpiSC)和B淋巴细胞。EpiSC表达中间丝角蛋白5和14,并形成由粘附物和桥粒连接连接的细胞片。相反,B淋巴细胞不表达角蛋白中间丝。它们表达一组确定的细胞表面蛋白,具有充分研究的表达动力学。为了使B淋巴细胞产生特异性免疫球蛋白,它必须引起永久性的遗传变化。这涉及VDJ片段在其免疫球蛋白重链基因座中的缺失和重排。这种重排由RAG 1和RAG 2重组酶以及Pax 5编码的转录因子BSAP(B细胞特异性激活蛋白)介导。EpiSC不表现出VDJ重排;表达RAG 1、RAG 2或Pax 5基因;或产生免疫球蛋白。我们的初步数据表明,EpiSCs可以被定向表达B淋巴细胞标志物和基因,并显示VDJ片段的重排。我们假设EpiSC在发育上是灵活的,即它们可以被引导产生交替谱系的细胞。为了验证这一假设,在目的1中,我们提出引导EpiSC(用2gal标记)转分化成B淋巴细胞。我们将通过检测B细胞表面标志物和重组酶基因,并通过PCR分析2gal表达细胞中的VDJ重排来验证单个EpiSC确实转分化。由于转分化事件的持久性对于未来的治疗是重要的,我们将测试当从B细胞诱导环境中移除时,改变其细胞谱系的EpiSC是否保持转分化。在目标2中,我们将尝试确定单个EpiSC转分化的机制。我们的初步研究结果表明,EpiSCs需要与S17基质细胞直接接触才能转分化。我们假设S17细胞通过受体-配体相互作用诱导EpiSC改变其谱系。我们将通过在与S17细胞共培养之前和期间检查EpiSCs的膜来测试这一假设,以检测候选受体-配体对的表达。由于皮肤是最大的器官,具有潜在的最大数量的干细胞,了解这些细胞转分化背后的机制是朝着它们在组织再生中的应用迈出的一步。许多疾病,包括糖尿病、老年痴呆症和心脏病,都是由主要器官中的细胞死亡引起的。为了治疗这些疾病,丢失的细胞必须被替换,最好是用自体细胞。这样的细胞将不得不被诱导改变其谱系并移植到新的环境中,这一过程统称为转分化。来自表皮(皮肤的外层)的干细胞提供了优于其他类型的成体干细胞的优势,因为它们可以分离而对个体几乎没有伤害,并且由于皮肤是身体中最大的器官,它们大量存在。因此,确定表皮干细胞转分化及其组织再生潜力的机制具有临床意义。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JACKIE R BICKENBACH其他文献
JACKIE R BICKENBACH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JACKIE R BICKENBACH', 18)}}的其他基金
Role of OCT4 in reprogramming human skin keratinocytes
OCT4在人皮肤角质形成细胞重编程中的作用
- 批准号:
8197353 - 财政年份:2009
- 资助金额:
$ 16.13万 - 项目类别:
Role of OCT4 in reprogramming human skin keratinocytes
OCT4在人皮肤角质形成细胞重编程中的作用
- 批准号:
7996059 - 财政年份:2009
- 资助金额:
$ 16.13万 - 项目类别:
Role of OCT4 in reprogramming human skin keratinocytes
OCT4在人皮肤角质形成细胞重编程中的作用
- 批准号:
7577192 - 财政年份:2009
- 资助金额:
$ 16.13万 - 项目类别:
Role of OCT4 in reprogramming human skin keratinocytes
OCT4在人皮肤角质形成细胞重编程中的作用
- 批准号:
7754673 - 财政年份:2009
- 资助金额:
$ 16.13万 - 项目类别:
Age-related Responses of Epidermal Stem Cells to Environ
表皮干细胞对环境的年龄相关反应
- 批准号:
7035837 - 财政年份:2002
- 资助金额:
$ 16.13万 - 项目类别:
Age-related Responses of Epidermal Stem Cells to Environ
表皮干细胞对环境的年龄相关反应
- 批准号:
6496987 - 财政年份:2002
- 资助金额:
$ 16.13万 - 项目类别:
Age-related Responses of Epidermal Stem Cells to Environ
表皮干细胞对环境的年龄相关反应
- 批准号:
6627846 - 财政年份:2002
- 资助金额:
$ 16.13万 - 项目类别:
Age-related Responses of Epidermal Stem Cells to Environ
表皮干细胞对环境的年龄相关反应
- 批准号:
6734215 - 财政年份:2002
- 资助金额:
$ 16.13万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 16.13万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 16.13万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 16.13万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 16.13万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 16.13万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 16.13万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 16.13万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 16.13万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 16.13万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 16.13万 - 项目类别:














{{item.name}}会员




